Literature DB >> 26548511

Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism.

A Prakash1, C Sharma1, A Singh1, P Kumar Singh1, A Kumar2, F Hagen3, N P Govender4, A L Colombo5, J F Meis6, A Chowdhary7.   

Abstract

Candida auris is a multidrug-resistant nosocomial bloodstream pathogen that has been reported from Asian countries and South Africa. Herein, we studied the population structure and genetic relatedness among 104 global C. auris isolates from India, South Africa and Brazil using multilocus sequence typing (MLST), amplified fragment length polymorphism (AFLP) fingerprinting and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). RPB1, RPB2 and internal transcribed spacer (ITS) and D1/D2 regions of the ribosomal DNA were sequenced for MLST. Further, genetic variation and proteomic assessment was carried out using AFLP and MALDI-TOF MS, respectively. Both MLST and AFLP typing clearly demarcated two major clusters comprising Indian and Brazilian isolates. However, the South African isolates were randomly distributed, suggesting different genotypes. MALDI-TOF MS spectral profiling also revealed evidence of geographical clustering but did not correlate fully with the genotyping methods. Notably, overall the population structure of C. auris showed evidence of geographical clustering by all the three techniques analysed. Antifungal susceptibility testing by the CLSI microbroth dilution method revealed that fluconazole had limited activity against 87% of isolates (MIC90, 64 mg/L). Also, MIC90 of AMB was 4 mg/L. Candida auris is emerging as an important yeast pathogen globally and requires reproducible laboratory methods for identification and typing. Evaluation of MALDI-TOF MS as a typing method for this yeast is warranted.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amplified fragment length polymorphism; Candida auris; D1/D2; RPB1; RPB2; internal transcribed spacer; matrix-assisted laser desorption ionization time-of-flight mass spectrometry

Mesh:

Substances:

Year:  2015        PMID: 26548511     DOI: 10.1016/j.cmi.2015.10.022

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  55 in total

1.  In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination.

Authors:  J Meletiadis; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 2.  Candida auris: a Review of the Literature.

Authors:  Anna Jeffery-Smith; Surabhi K Taori; Silke Schelenz; Katie Jeffery; Elizabeth M Johnson; Andrew Borman; Rohini Manuel; Colin S Brown
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

3.  Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome.

Authors:  Ziauddin Khan; Suhail Ahmad; Khalifa Benwan; Prashant Purohit; Inaam Al-Obaid; Ritu Bafna; Maha Emara; Eiman Mokaddas; Aneesa Ahmed Abdullah; Khaled Al-Obaid; Leena Joseph
Journal:  Infection       Date:  2018-06-14       Impact factor: 3.553

4.  Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods.

Authors:  J Meletiadis; E Geertsen; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

5.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.

Authors:  Shawn R Lockhart; Kizee A Etienne; Snigdha Vallabhaneni; Joveria Farooqi; Anuradha Chowdhary; Nelesh P Govender; Arnaldo Lopes Colombo; Belinda Calvo; Christina A Cuomo; Christopher A Desjardins; Elizabeth L Berkow; Mariana Castanheira; Rindidzani E Magobo; Kauser Jabeen; Rana J Asghar; Jacques F Meis; Brendan Jackson; Tom Chiller; Anastasia P Litvintseva
Journal:  Clin Infect Dis       Date:  2016-10-20       Impact factor: 9.079

6.  Candida auris for the clinical microbiology laboratory: Not your grandfather's Candida species.

Authors:  Shawn R Lockhart; Elizabeth L Berkow; Nancy Chow; Rory M Welsh
Journal:  Clin Microbiol Newsl       Date:  2017-07-01

7.  Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.

Authors:  Alexander J Lepak; Miao Zhao; Elizabeth L Berkow; Shawn R Lockhart; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  Performance of Two Novel Chromogenic Media for the Identification of Multidrug-Resistant Candida auris Compared with Other Commercially Available Formulations.

Authors:  Auke W de Jong; Chendo Dieleman; Mauricio Carbia; Ratna Mohd Tap; Ferry Hagen
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

Review 9.  Candida auris: an Emerging Fungal Pathogen.

Authors:  Emily S Spivak; Kimberly E Hanson
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

Review 10.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.